During therapy, CLL patients treated with ibrutinib exhibited a gradual decrease in NOTCH1 activity, which was later reestablished upon relapse and persisted in cases of ibrutinib-resistant disease [36]. The gene discussed is NOTCH1; the disease is B-cell chronic lymphocytic leukemia.